Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 70.25

+0.1%

Nov 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (50)	9/27/2002 4:02:07 PM
From: Jibacoa	of 3722

BSX Is also on the black column today and it seems headed to test its June 20 H at 32.50 It reported yesterday the results of the TAXUS II trial on 537 patients, which showed a major decrease in restenosis 6 months after placement of a paclitaxel-eluting stent. The reults showed that restenosis occurred in 5.5% of patients fitted with stents containing paclitaxel, compared with 20.1% restenosis for a control group. JNJ's SIRIUS trial had shown the benefit from Sirolimus, and now the TAXUS stent seems to be working very well also. That's is good news for the patients,BSX and interventional cardiologist as well.<g> siliconinvestor.com siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next